Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 14;8(6):e1044.
doi: 10.1002/cti2.1044. eCollection 2019.

Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics

Joana A Revez  1 , Lisa M Bain  1 , Rick M Watson  2 , Michelle Towers  3 , Tina Collins  3 , Kieran J Killian  2 , Paul M O'Byrne  2 , Gail M Gauvreau  2 , John W Upham  3 , Manuel Ar Ferreira  1
Affiliations

Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics

Joana A Revez et al. Clin Transl Immunology. .

Abstract

Background: Interleukin (IL)-6 signalling has been implicated in allergic asthma by animal, genetic association and clinical studies. In this study, we tested the hypothesis that tocilizumab (TCZ), a human monoclonal antibody that blocks IL-6 signalling, can prevent the development of allergen-induced bronchoconstriction in humans.

Methods: We performed a randomised, double-blind, placebo-controlled study, with eligible participants completing two allergen inhalation challenge tests, conducted before and after treatment with a single dose of TCZ or placebo. The primary efficacy endpoint was the magnitude of the late asthmatic response recorded between 3 and 7 after allergen challenge. The secondary efficacy endpoint was the early asthmatic response, measured 20 min to 2 h after allergen challenge.

Results: A total of 66 patients enrolled between September 2014 and August 2017, when the trial was stopped for futility based on results from an interim analysis. Eleven patients fulfilled all eligibility criteria assessed at baseline and were subsequently randomised to the TCZ (n = 6) or placebo (n = 5) groups. Both the primary and secondary efficacy endpoints were not significantly different between the two groups. Five patients reported adverse events (AEs), three in the TCZ group (11 AEs) and two in the placebo group (four AEs). Only one AE was TCZ-related (mild neutropenia), and there were no serious AEs. Significant treatment effects were observed for serum levels of C-reactive protein, IL-6 and soluble IL-6R levels.

Conclusion: In a small proof-of-concept clinical trial, we found no evidence that a single dose of tocilizumab was able to prevent allergen-induced bronchoconstriction. (Trial registered in the Australian New Zealand Clinical Trials Registry, number ACTRN12614000123640).

Keywords: GWAS; IL6; IL6R; actemra; allergy; rs2228145; trans‐signalling.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design. Arrow indicates the day on which tocilizumab or placebo was administered. Crosses indicate the days on which each procedure was performed. ACT: allergen challenge test. AHR: airway hyperresponsiveness test. SI: sputum induction. PB: peripheral blood collection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Neutrophils and Asthma.
    Yamasaki A, Okazaki R, Harada T. Yamasaki A, et al. Diagnostics (Basel). 2022 May 8;12(5):1175. doi: 10.3390/diagnostics12051175. Diagnostics (Basel). 2022. PMID: 35626330 Free PMC article. Review.
  • Identification of Druggable Genes for Asthma by Integrated Genomic Network Analysis.
    Adikusuma W, Chou WH, Lin MR, Ting J, Irham LM, Perwitasari DA, Chang WP, Chang WC. Adikusuma W, et al. Biomedicines. 2022 Jan 6;10(1):113. doi: 10.3390/biomedicines10010113. Biomedicines. 2022. PMID: 35052792 Free PMC article.
  • Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review.
    Spahn JD, Brightling CE, O'Byrne PM, Simpson LJ, Molfino NA, Ambrose CS, Martin N, Hallstrand TS. Spahn JD, et al. J Asthma Allergy. 2023 Jul 21;16:755-774. doi: 10.2147/JAA.S410592. eCollection 2023. J Asthma Allergy. 2023. PMID: 37496824 Free PMC article. Review.
  • Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dichotomic Paradigm.
    Ramirez GA, Cardamone C, Lettieri S, Fredi M, Mormile I. Ramirez GA, et al. Clin Rev Allergy Immunol. 2025 Feb 11;68(1):13. doi: 10.1007/s12016-024-09020-3. Clin Rev Allergy Immunol. 2025. PMID: 39932658 Free PMC article. Review.
  • Genome-wide association study of circulating interleukin 6 levels identifies novel loci.
    Ahluwalia TS, Prins BP, Abdollahi M, Armstrong NJ, Aslibekyan S, Bain L, Jefferis B, Baumert J, Beekman M, Ben-Shlomo Y, Bis JC, Mitchell BD, de Geus E, Delgado GE, Marek D, Eriksson J, Kajantie E, Kanoni S, Kemp JP, Lu C, Marioni RE, McLachlan S, Milaneschi Y, Nolte IM, Petrelis AM, Porcu E, Sabater-Lleal M, Naderi E, Seppälä I, Shah T, Singhal G, Standl M, Teumer A, Thalamuthu A, Thiering E, Trompet S, Ballantyne CM, Benjamin EJ, Casas JP, Toben C, Dedoussis G, Deelen J, Durda P, Engmann J, Feitosa MF, Grallert H, Hammarstedt A, Harris SE, Homuth G, Hottenga JJ, Jalkanen S, Jamshidi Y, Jawahar MC, Jess T, Kivimaki M, Kleber ME, Lahti J, Liu Y, Marques-Vidal P, Mellström D, Mooijaart SP, Müller-Nurasyid M, Penninx B, Revez JA, Rossing P, Räikkönen K, Sattar N, Scharnagl H, Sennblad B, Silveira A, Pourcain BS, Timpson NJ, Trollor J; CHARGE Inflammation Working Group; van Dongen J, Van Heemst D, Visvikis-Siest S, Vollenweider P, Völker U, Waldenberger M, Willemsen G, Zabaneh D, Morris RW, Arnett DK, Baune BT, Boomsma DI, Chang YC, Deary IJ, Deloukas P, Eriksson JG, Evans DM, Ferreira MA, Gaunt T, Gudnason V, Hamsten A, Heinrich J, Hingorani A, Humphries SE, Jukema JW, Koenig W, Kum… See abstract for full author list ➔ Ahluwalia TS, et al. Hum Mol Genet. 2021 Apr 27;30(5):393-409. doi: 10.1093/hmg/ddab023. Hum Mol Genet. 2021. PMID: 33517400 Free PMC article.
See all "Cited by" articles

References

    1. Yoshizaki K, Nakagawa T, Fukunaga K, et al Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol (Baltimore, Md: 1950) 1984; 132: 2948–2954. - PubMed
    1. Becker S, Quay J, Soukup J. Cytokine (tumor necrosis factor, IL‐6, and IL‐8) production by respiratory syncytial virus‐infected human alveolar macrophages. J Immunol 1991; 147: 4307–4312. - PubMed
    1. Cicco NA, Lindemann A, Content J, et al Inducible production of interleukin‐6 by human polymorphonuclear neutrophils: role of granulocyte‐macrophage colony‐stimulating factor and tumor necrosis factor‐alpha. Blood 1990; 75: 2049–2052. - PubMed
    1. Cromwell O, Hamid Q, Corrigan CJ, et al Expression and generation of interleukin‐8, IL‐6 and granulocyte‐macrophage colony‐stimulating factor by bronchial epithelial cells and enhancement by IL‐1 beta and tumour necrosis factor‐alpha. Immunology 1992; 77: 330–337. - PMC - PubMed
    1. Zola H, Flego L. Expression of interleukin‐6 receptor on blood lymphocytes without in vitro activation. Immunology 1992; 76: 338–340. - PMC - PubMed

LinkOut - more resources